23andMe Holding Co. (ME) Earnings Per Share (EPS): -9.05
Is 23andMe Holding Co.’s earnings per share (EPS) high or low?
23andMe Holding Co.'s earnings per share (EPS) of -9.05 is 36% above its 5-year average of -14.25, near the high end of its 5-year range (-27.59–-9.02).
As of Thursday, June 18, 2026. 52.95% above its 12-month average of -19.23.
ME Earnings Per Share (EPS) Chart
ME Average Earnings Per Share (EPS) Chart
ME Current vs Average Earnings Per Share (EPS) Chart
ME Earnings Per Share (EPS) Metrics
EARNINGS PER SHARE (EPS)
-9.05
EARNINGS PER SHARE (EPS) AVG TTM
-19.23
EARNINGS PER SHARE (EPS) AVG 3Y
-15.56
EARNINGS PER SHARE (EPS) AVG 5Y
-14.25
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+52.95%
CURRENT VS 3Y AVG
+41.84%
CURRENT VS 5Y AVG
+36.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Earnings Per Share (EPS)
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -9.05 | -19.23 | -15.56 | -14.25 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | -3.15 | -3.74 | -3.13 | -1.84 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 6.07 | -18.74 | -45.28 | 14.90 |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | -0.09 | 0.57 | 0.18 | -0.06 |
| Tempus AI, Inc. (TEM)vs › | $8.66B | -1.72 | -3.00 | -2.43 | -2.16 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | -3.76 | -1.35 | 4.03 | 5.21 |
| Baxter International Inc. (BAX)vs › | $10.29B | -2.10 | -1.51 | -0.65 | 0.36 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.29 | -6.79 | -1.56 | -0.26 |
| Revvity, Inc. (RVTY)vs › | $11.07B | 2.10 | 2.25 | 2.01 | 3.78 |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 1.18 | 1.92 | 1.82 | 11.98 |
EPS Comparison
Trailing EPS (TTM)
$-9.05
Forward EPS (Est.)
$-10.64
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
- Directly impacts stock valuation through P/E ratio
- Used to calculate dividend coverage and payout ratios
- Enables comparison across companies of different sizes
- Growth in EPS often correlates with stock price appreciation
23andMe Holding Co. Earnings Per Share (EPS) Formula & Definition
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Earnings Per Share (EPS) FAQ
- What is the earnings per share (EPS) for 23andMe Holding Co. (ME)?
- The earnings per share (EPS) for ME stock is -9.05.
- Is 23andMe Holding Co.'s earnings per share (EPS) high or low?
- 23andMe Holding Co.'s earnings per share (EPS) of -9.05 is 36% above its 5-year average of -14.25, near the high end of its 5-year range (-27.59–-9.02).
- What is the TTM average earnings per share (EPS) for 23andMe Holding Co. (ME)?
- The TTM average earnings per share (EPS) for ME stock is -19.23.
- What is the 3Y average earnings per share (EPS) for 23andMe Holding Co. (ME)?
- The 3Y average earnings per share (EPS) for ME stock is -15.56.
- What is the 5Y average earnings per share (EPS) for 23andMe Holding Co. (ME)?
- The 5Y average earnings per share (EPS) for ME stock is -14.25.
23andMe Holding Co. Earnings Per Share (EPS) History
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-03-31 | -10.88 |
| 2024-03-31 | -27.59 |
| 2023-03-31 | -13.81 |
| 2022-03-31 | -9.96 |
| 2021-03-31 | -9.02 |
| 2020-03-31 | -14.24 |
| 2019-03-31 | -9.03 |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage